Henry Schein this week announced it completed the previously announced acquisition of majority interest in Shield Healthcare.
The company announced the deal in August as officials saw the move as bolstering the company’s commitment to facilitating a continuum-of-care delivery model.
Henry Schein expects the transaction to be neutral to 2023 non-GAAP earnings per share and accretive thereafter. Financial terms were not disclosed.
Valencia, California-based Shield Healthcare operates in the home care medical supplies space. It had net sales of around $180 million in 2022. The acquisition expands Henry Stein’s home care medical products portfolio.
“As the health care landscape continues to shift towards home-based case, we have expanded our business delivering medical products directly to patients through our partnership with Shield Healthcare,” Henry Schein CEO Stanley Bergman said in a news release. “Through our strategic homecare products investments, our Henry Schein Medical business is increasingly well positioned to compete in the homecare medical supplies market. By combining our strong physician relationships, product distribution expertise, and corporate brand assortment, we are well-positioned for growth in this market segment. We welcome our new Shield Healthcare colleagues to Team Schein, and we look forward to continued success together.”
This acquisition builds on Henry Stein’s 2021 purchase of Prism Medical Products. It includes products such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, it will offer continuous glucose monitoring devices directly to patients in their homes.
